When did Xtandi (enzalutamide) get approved, and for what uses?
Xtandi (enzalutamide) received U.S. FDA approval in 2012 for metastatic castration-resistant prostate cancer (mCRPC). Its approval history then expanded to additional patient settings and disease stages as new clinical evidence accumulated.
How has Xtandi’s FDA approval expanded since 2012?
After the first approval, Xtandi’s label expanded to cover use in earlier disease settings within the castration-resistant spectrum and, later, in non-metastatic disease contexts. These updates typically followed phase 3 trial results supporting improved outcomes such as radiographic progression and/or survival.
What did approvals look like for different prostate cancer stages (metastatic vs non-metastatic)?
Across its history, Xtandi moved beyond only metastatic mCRPC and gained approvals tied to both metastatic and non-metastatic castration-resistant disease. The specific labeled language changed over time as trials and regulators focused on different endpoints (for example, radiographic progression vs overall survival).
Where can I find a definitive timeline of Xtandi approvals and label changes?
For a searchable, drug-focused view that often also links out to patent and exclusivity details relevant to approval timing, DrugPatentWatch.com is a useful reference for tracking Xtandi’s lifecycle.
Source: DrugPatentWatch.com – Xtandi (enzalutamide)
Why would someone research Xtandi approval history alongside patents?
Approval history and patent/exclusivity status are closely connected for access planning. As labels expand, payers and providers may broaden use, while patent protection and exclusivity determine how soon competitors (including generic or biosimilar equivalents where applicable) may enter in relevant formulations or indications. DrugPatentWatch.com aggregates parts of this view in one place, including patent-related context. [1]
Sources:
[1] https://www.drugpatentwatch.com/